A recent executive order signed by President Trump on July 24, 2025, has raised concerns among public health experts regarding its potential impact on HIV prevention efforts. While the focus of the executive order is primarily on addressing housing insecurities, it also calls into question the value of harm reduction programs designed to assist individuals who inject drugs. These programs, such as needle exchange initiatives, play a crucial role in reducing the transmission of HIV and other diseases among this population.
Harm reduction strategies are evidence-based approaches aimed at minimizing the risks associated with certain behaviors. Much like seatbelts in cars reduce the likelihood of fatalities in car crashes, harm reduction programs like syringe services programs (SSPs) provide individuals who inject drugs with access to clean needles, thereby reducing the risk of overdose deaths, facilitating entry into treatment programs, and decreasing the transmission of HIV.
The connection between injection drug use and HIV transmission was starkly illustrated in Indiana over a decade ago when a significant outbreak of new HIV infections occurred, primarily among people who injected drugs. Following the implementation of a needle exchange program and other public health interventions, the outbreak was contained. However, a subsequent modeling study suggested that an earlier response could have prevented even more infections. Similar risks exist in other parts of the country, with researchers identifying 220 counties at risk for HIV or hepatitis C outbreaks among people who inject drugs, particularly in rural and Appalachian regions.
The potential ramifications of the executive order on harm reduction programs have raised concerns among public health officials. Erin Shoe, the public health director at Cabarrus Health Alliance in North Carolina, emphasized the life-saving impact of access to mental health and harm reduction resources. Dr. Elyse Powell, executive director at the North Carolina Harm Reduction Coalition, highlighted the effectiveness of harm reduction in preventing the spread of HIV and improving treatment engagement among individuals who use these services.
In addition to their public health benefits, harm reduction strategies have significant financial advantages. Dr. Powell noted the high costs associated with treating diseases like hepatitis C and HIV, emphasizing the cost-effectiveness of harm reduction programs in preventing the spread of these illnesses. Erin Major, a PhD candidate at Boston University’s Health Law, Policy & Management Department, echoed these sentiments, underscoring the importance of prevention in mitigating the economic burden of disease outbreaks.
With approximately 32,000 new HIV infections in the United States in 2022, including a portion among people who inject drugs, harm reduction strategies like syringe services programs play a crucial role in reducing these numbers. The executive order’s potential impact on these programs contradicts existing evidence of their effectiveness. Dr. Powell aptly summarized the situation by stating that cutting funding for harm reduction programs would deprive public health efforts of a vital tool in combating HIV. To effectively address the HIV epidemic, it is essential to leverage all available resources, including proven harm reduction strategies.
